JPMorgan analyst Anupam Rama reiterated an Underweight rating on Mirati Therapeutics (NASDAQ: MRTX) ahead of abstracts for the AACR-NCI-EORTC International ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE